The messenger under attack - Intimidation of researchers by special- interest groups

New England Journal of Medicine

Volumn 336, Issue 16, 1997, Pages 1176-1180

  Deyo, Richard A ^a,c   Psaty, Bruce M ^a   Simon, Gregory ^b   Wagner, Edward H ^b   Omenn, Gilbert S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c Center for Cost and Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH HAZARD; HUMAN; HYPERTENSION; LAW SUIT; MEDICAL RESEARCH; MULTIPLE CHEMICAL SENSITIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; SPINE FUSION; SPINE SURGERY;

BIOMEDICAL AND BEHAVIORAL RESEARCH; BIOMEDICAL RESEARCH; CLINICAL APPROACH/SOURCE; HEALTH HAZARDS; INFORMATION DISSEMINATION; POLITICAL ACTIVITY; PUBLIC PARTICIPATION; UNITED STATES;

BIOMEDICAL RESEARCH; CALCIUM CHANNEL BLOCKERS; COMMUNICATION; HUMANS; INFORMATION DISSEMINATION; INTERNAL FIXATORS; MULTIPLE CHEMICAL SENSITIVITY; MYOCARDIAL INFARCTION; POLITICS; PUBLISHING; RESEARCH; SOCIAL VALUES; SPINAL FUSION; TRUTH DISCLOSURE; UNITED STATES;

EID: 0030765130     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199704173361611     Document Type: Article

References (26)

1. Feinstein AR. Clinical judgment. Huntington, N.Y.: Robert E. Krieger, 1967:220-2.
2. Angell M. Evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. N Eng J Med 1996;334: 1513-8.
3. Gabriel SE, O'Fallon WM, Kurland LT, Beard CM, Woods JE, Melton LJ III. Risk of connective-tissue diseases and other disorders after breast implantation. N Engl J Med 1994;330:1697-702.
4. Needleman HL, Gunnoe C, Leviton A, et al. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N Engl J Med 1979;300:689-95. [Erratum, N Engl J Med 1994;331: 616.]
5. Needleman HL. Salem comes to the National Institutes of Health: notes from inside the crucible of scientific integrity. Pediatrics 1992;90: 977-81.
6. Silbergeld EK. Annotation: protection of the public interest, allegations of scientific misconduct, and the Needleman case. Am J Public Health 1995;85:165-6.
7. Kassirer JP. A partisan assault on science - the threat to the CDC. N Engl J Med 1995;333:793-4.
8. Deyo RA, Cherkin DC, Loeser JD, Bigos SJ, Ciol MA. Morbidity and mortality in association with operations on the lumbar spine: the influence of age, diagnosis, and procedure. J Bone Joint Surg Am 1992;74: 536-43.
9. Deyo RA, Ciol MA, Cherkin DC, Loeser JD, Bigos SJ. Lumbar spinal fusion: a cohort study of complications, reoperations, and resource use in the Medicare population. Spine 1993;18:1463-70.
10. Turner JA, Ersek M, Herron L, et al. Patient outcomes after lumbar spinal fusions. JAMA 1992;268:907-11.
11. Simon GE, Daniell W, Stockbridge H, Claypoole K, Rosenstock L. Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity: a controlled study. Ann Intern Med 1993;119:97-103.
12. Daniell WE. Science, integrity, and investigators' rights: current challenges. Regul Toxicol Pharmacol 1996;24:S152-S162.
13. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. Circulation 1995;91:925. abstract.
14. Horton R. Bayer accused of disinformation. Lancet 1995;346:891-2.
15. Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986;56:400-13.
16. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345-53.
17. Lichtlen PR, Hugenholtz PG, Rafflenbcul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990;335:1109-13.
18. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92: 1326-31.
19. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-5.
20. Pring GW, Canan P. SLAPPs: an introduction for bench, bar and bystanders. Bridgeport Law Rev 1992;12:937-62.
21. Canan P, Kretzmann M, Hennessy M, Pring GW. Using law ideologically: the conflict between economic and political liberty. J Law Polit 1992;8:539-58.
22. Black B. Subpoenas and science - when lawyers force their way into the laboratory. N Engl J Med 1997;336:725-7.
23. National Heart, Lung, and Blood Institute. Statement: calcium-channel blockers for hypertension. Bethesda, Md.: National Institutes of Health, March 14, 1995.
24. Idem. Statement: new analyses regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Bethesda, Md.: National Institutes of Health, September 1, 1995.
25. Hershey N. The clinical investigator as target. Control Clin Trials 1996;17:183-90.
26. Donaldson MS, Capron AM, eds. Patient outcomes research teams: managing conflict of interest. Washington, D.C.: National Academy Press, 1991.